CytoSorbents (CTSO)
Develops blood-purification cartridges for critical care and cardiac surgery, commercializing CytoSorb internationally.
Something off on this page? Send us feedback.
Develops and commercializes blood-purification cartridges based on porous-polymer technology. CytoSorb is the flagship product, while ECOS-300CY and VetResQ are marketed and DrugSorb-ATR is advancing toward North American authorization.
Develops and commercializes blood-purification cartridges based on porous-polymer adsorbent technology for critical care and cardiac surgery. CytoSorb is the flagship product, alongside marketed ECOS-300CY and VetResQ, while CytoSorb XL and DrugSorb-ATR remain in development.
CytoSorb is CE-marked in the European Union and distributed in more than 70 countries. A New Jersey medical-device subsidiary handles research, development, and commercialization, while European, Indian, and Dubai subsidiaries conduct sales and marketing.
CytoSorb is not authorized, cleared, or approved in the United States. DrugSorb-ATR, for antithrombotic-drug removal in cardiothoracic surgery, remains investigational there; North American commercialization depends on resolving regulatory deficiencies and obtaining authorization.
Company facts
Categories
No analyst consensus on record.
EPSReportedEstimate
RevenueReportedEstimate
Balance sheet, Jun 30, 2026Cash & short-term investments $4.4M · Total debt $26.3M · Total assets $38.0M · Shareholders' equity −$751.0K
- Revenue
- $9.6M
- Operating income
- −$2.6M
- Net income
- −$4.4M
No dividends on record.
| Institutions50 holders · as of Mar 31, 2026 | 26.21% | 16.47M shares | |
| Insiders6 holders · as of Jun 16, 2026 | 9.82% | 6.17M shares | |
| Otherremainder | 63.97% | 40.20M shares |
62.84M company shares as of Sep 3, 2026 · institutions as of Mar 31, 2026 · holders as of their latest filing
Top shareholders13F · 13D/G · Form 4
| Holder | Stake | Shares | Evidence |
|---|---|---|---|
Avenir CorpInstitution | 8.30% | 5.22M | 13Fas of Mar 31, 2026 |
Thomas A. Satterfield, Jr.Insider | 6.36% | 4.00M | 13Gfiled Jan 17, 2025 ↗ |
Granahan Investment Management LLCInstitution | 5.76% | 3.62M | 13Gfiled Feb 14, 2024 ↗ |
Vanguard Capital Management LLCInstitution | 2.99% | 1.88M | 13Fas of Mar 31, 2026 |
Skylands Capital, LLCInstitution | 2.72% | 1.71M | 13Fas of Mar 31, 2026 |
| See all 25 → | |||
13F — a manager's quarterly holdings · 13D/13G — an ownership statement filed at 5% or more
Insider tradesForm 4
| Date | Insider | Role | Shares | Avg price |
|---|---|---|---|---|
| Jun 15, 2026 | Peter J. Mariani | officer: Chief Financial Officer | +100,000 | $0.4400 |
| Jun 12, 2026 | Phillip P. Chan | director, officer: Chief Executive Officer | +251,136 | $0.4000 |
| Jun 15, 2026 | Phillip P. Chan | director, officer: Chief Executive Officer | +10,333 | $0.4300 |
- SeaStar Medical
Extracorporeal immunomodulation for sepsis-associated AKI
ComparePre-market
| Company | Price | Change | |||||
|---|---|---|---|---|---|---|---|
| CytoSorbents | $0.3398 | −11.88% | $24.1M | — | — | 0.6 | +0.2% |
| SeaStar Medical | $2.90 | −2.87% | $8.2M | — | — | 4.8 | +82.0% |
| Median | — | — | 4.8 | +82.0% |